CooperVision-Sponsored Research Among Multiple Scientific Works Presented with Clinical and University Partners
Preliminary results from a new study indicate that individual question responses within the widely-used Ocular Surface Disease Index (OSDI) symptom questionnaire can be correlated to specific clinical measures, providing eye care professionals better insight on treatment pathways. The CooperVision-supported work is being presented at the ARVO 2023 Annual Meeting this week.
Association of Clinical Signs with the Ocular Surface Disease Index: Preliminary Results from the
Multicenter Neurosensory Abnormalities in ocular SurfAce Disease Study (Hom M., et al.) from the NASA Study Group probes deeper than past reports of overall OSDI score correlations. The multicenter, prospective, cross-sectional investigation assessed patients who presented for ocular surface disease care. In addition to completion of the OSDI, measures were taken for tear break-up time (TBUT), corneal fluorescein staining (CFS), lissamine green conjunctival staining (LGS), Schirmer’s test, and meibomian gland grading (MGG).
Preliminary analysis included 250 participants across 13 sites. Significant correlations were identified between decreased TBUT and difficulty reading (r=-0.166, p=0.009). Increased CFS was associated with increased frequency of gritty sensation (r=0.166, p=0.008). Decreased Schirmer’s test was associated with increased symptom frequency in windy conditions (r=-0.195, p=0.002). MGG and LGS show no significant correlations.
“These outcomes should help eye care professionals derive even more value from their OSDI questionnaires, pointing them toward potential underlying issues and treatments,” said Anna Sulley, BSc(Hons), MCOptom, FAAO, FBCLA, Director, Global Medical Affairs at CooperVision. “We’re privileged to partner with some of the top researchers and institutions in ocular science, with the aim of improving fundamental clinical practice. The works being shared at ARVO 2023 reflect this collaborative spirit.”
An additional CooperVision-supported study on display in New Orleans demonstrates the effect of ceasing and then restarting contact lens use after three months in symptomatic wearers as measured by psychophysical responses to repetitive cooling stimuli.
The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting is the premiere gathering for eye and vision scientists, students, affiliated professionals to review the field’s research findings and collaborate on innovative solutions. It runs from April 23 – 27, 2023, at the New Orleans Ernest N. Morial Convention Center.
# # #
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies (“Cooper”) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com
Mike McDougall, APR, Fellow PRSA, FAAO, McDougall Communications
email@example.com or +1-585-434-2150